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Abstract 
Background 
Next to Alzheimer’s disease, Parkinson’s disease (PD) is the second most 
neurodegenerative disease1.  As the population structure in the industrialized and 
industrializing countries is changing, an increasing prevalence of diseases typical for 
the elderly is projected within the next decades. The burden of disease, cost driving 
factors and the effectiveness of disease management options are therefore important 
information, as health and social care systems must prepare for a rising demand for 
economic resources and trained personnel within the health care sector. 
Objectives 
The objective of this thesis was to describe different aspects of the economic burden 
of PD as drug costs, institutional care, hospitalization and the cost-effectiveness of 
the disease management. 
Subjects  
In the first study we evaluated a group of 286 consecutive patients with PD searching 
free advice in a German counseling program and a group of 152 consecutive 
Norwegian patients with PD being followed at the outpatient clinic of the Stavanger 
University Hospital. 
In the second and third study we included the 108 patients with PD from a 
population-based prospective longitudinal study in Southern Rogaland, Norway, who 
were living in the municipality of Stavanger at baseline. Through the National 
registry we identified eight control subjects for every patient with PD that matched in 
sex and age and were living in Stavanger at baseline. 
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In the fourth study we included 199 patients participating in a population-based 
prospective longitudinal study of patients with incident PD from Western and 
Southern Norway. Among relatives and acquaintances of the patients 205 controls 
were recruited. We included a subset of 172 control individuals who provided the 
best possible group match regarding sex, age and education and complete information 
about their health status. 
Methods 
In the first study data about disease duration, disease severity as measured by Hoehn 
and Yahr (HY) stage2, and drug use were collected for both patient groups in a cross-
sectional study design. 
In the second study, for patients with PD data about disease duration, disease severity 
as measured by HY stage, cognitive functioning as measured by the Mini Mental 
State Examination (MMSE)3, date of permanent admission to a nursing home and 
date of death were collected from the patient files and the municipality’s registration 
systems during a 12-year observation period. For controls, data about age, date of 
admission to a nursing home and date of death were collected from the municipality’s 
registration systems and the National registry. 
In the third study data about hospital admissions, length of stay and diagnoses at 
discharge were collected from the files of the Stavanger University Hospital for 
patients and controls over a 12-year observation period. 
In the fourth study, for the patients with PD data about disease severity as measured 
by HY stage and the Unified Parkinson’s Disease Rating Scale (UPDRS)4, health 
status as measured by the Short form 36 (SF-36)5 and drug use was registered during 
the first year of medical treatment. For controls independency in daily living as 
measured by the UPDRS part II and the SF-36 were registered during the same 
period. To evaluate health state values, the data of the SF-36 were converted to the 
Short Form-6D (SF-6D)6. 
Results 
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We found that drug expenses rose with disease duration and disease severity both in 
the German and the Norwegian study cohort. However, expenses were markedly 
higher in the German cohort with Euro 5.78 versus Euro 3.92 per patient and day, 
partly due to an earlier switch from mono- to multi-drug therapy during the course of 
the disease. 
Patients with PD had a five-fold higher risk for living in a nursing home as compared 
to controls. Based on 2007 prices, the incremental costs for institutional care were 
Euro 14 897 per person year of survival.  
There was no significant difference between patients with PD and controls regarding 
the number of individuals being admitted to hospital, numbers of admission, or length 
of stay. However, we found that patients with PD were more often admitted for 
trauma, while cardio-vascular diseases and cancer were markedly more common in 
control individuals. 
Patients with PD had significantly lower health state values as compared to controls. 
Patients starting on antiparkinsonian drugs had an improvement in utility scores of 
0.039 from 0.667 to 0.706. The  incremental cost-effectiveness ratio (ICER) was 
Euro 45 259 per quality adjusted life year (QALY) during the first year of treatment, 
of which two thirds were caused by drugs and one third by costs for clinical 
consultations.  
Conclusion 
We could show that the use of control cohorts adds valuable information to the 
evaluation of the burden of disease and helps to discern costs related to a certain 
disease from costs caused by general age-related morbidity. We could further show 
that prescription habits may differ markedly from country to country and that the 
ICER during the first year of treatment is high. Therefore, disease management 
should be monitored carefully to provide an optimal quality of treatment as well as 
cost-effectiveness. However, more research is necessary to evaluate the full burden of 
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PD and to explore efficacy and effectiveness of the different disease management 
options. 
 10
 
List of publications 
 
1. Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with 
Parkinson's disease in two different European countries. Acta Neurol Scand. 
2006;113:228-32. 
 
2. Vossius C, Nilsen OB, Larsen JP. Parkinson’s disease and nursing home 
placement: the economic impact of the need for care. Euro J Neurol 2009; 16 (2): 
194-200. 
 
3. Vossius C, Nilsen OB, Larsen JP. Parkinson’s disease and hospital admissions: 
frequencies, diagnoses and costs. (In press in Acta Neurologica Scandinavica.) 
 
4. Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug 
treatment in early-stage Parkinson’s disease. (Re-submitted after major revisions 
to Drugs and Aging, May 2009.) 
 
 
 
 
 
The published papers are reprinted with permission from John Wiley & Sons Ltd and 
Acta Neurologica Scandinavica. 
 11
Contents 
SCIENTIFIC ENVIRONMENT ......................................................................................................... 3 
ACKNOWLEDGEMENT .................................................................................................................... 4 
ABSTRACT ........................................................................................................................................... 6 
LIST OF PUBLICATIONS ............................................................................................................... 10 
CONTENTS ........................................................................................................................................ 11 
1. INTRODUCTION .................................................................................................................... 14 
1.1.1 Epidemiology .............................................................................................................. 15 
1.1.2 Etiology and risk factors ............................................................................................. 15 
1.1.3 Pathogenesis and pathophysiology ............................................................................. 16 
1.1.4 Clinical course and disease classification .................................................................. 17 
1.1.5 Diagnosis and differential diagnosis of PD ................................................................ 20 
1.1.6 Disease management .................................................................................................. 22 
1.1.7 Prognosis .................................................................................................................... 27 
1.2 HEALTH ECONOMICS .............................................................................................................. 28 
1.2.1 What influences health (other than health care)? (A) ................................................ 29 
1.2.2 What is health? (B) ..................................................................................................... 30 
1.2.3 Health care demand (C).............................................................................................. 30 
1.2.4 The supply of health care (D) ..................................................................................... 31 
1.2.5 Micro-economic evaluation at treatment level (E) ..................................................... 31 
1.2.5.1 Cost-consequences analysis ..................................................................................................... 32 
1.2.5.2 Cost-minimisation analysis...................................................................................................... 32 
1.2.5.3 Cost-effectiveness analysis (CEA) .......................................................................................... 33 
 12
1.2.5.4 Cost-utility analysis (CUA) ..................................................................................................... 34 
1.2.5.5 Cost benefit analysis (CBA) .................................................................................................... 34 
1.2.6 Market equilibrium (F) .............................................................................................. 34 
1.2.7 Evaluation on whole system level (G)     - equity versus effectiveness ...................... 35 
1.2.8 Planning, budgeting and monitoring mechanisms (H) .............................................. 36 
1.2.9 Quality adjusted life year (QALY).............................................................................. 37 
1.2.10 Disease adjusted life year (DALY) ............................................................................. 41 
1.3 THE ECONOMIC BURDEN OF PD ............................................................................................. 42 
2. AIMS OF THE STUDY .......................................................................................................... 46 
3. METHODS ............................................................................................................................... 47 
3.1 STUDY DESIGN ...................................................................................................................... 47 
3.1.1 Paper 1 ....................................................................................................................... 47 
3.1.2 Paper 2 ....................................................................................................................... 47 
3.1.3 Paper 3 ....................................................................................................................... 47 
3.1.4 Paper 4 ....................................................................................................................... 47 
3.2 PATIENT SELECTION .............................................................................................................. 47 
3.2.1 Paper 1 ....................................................................................................................... 47 
3.2.2 Paper 2 and 3 ............................................................................................................. 48 
3.2.3 Paper 4 ....................................................................................................................... 49 
3.3 CONTROL SUBJECTS .............................................................................................................. 49 
3.3.1 Paper 2 and 3 ............................................................................................................. 49 
3.3.2 Paper 4 ....................................................................................................................... 50 
3.4 ASSESSMENT OF CLINICAL DATA ........................................................................................... 50 
3.4.1 Paper 1 ....................................................................................................................... 50 
 13
3.4.2 Paper 2 ........................................................................................................................ 51 
3.4.3 Paper 3 ........................................................................................................................ 51 
3.4.4 Paper 4 ........................................................................................................................ 51 
3.5 ASSESSMENTS OF COSTS ........................................................................................................ 52 
3.5.1 Paper 1 ........................................................................................................................ 52 
3.5.2 Paper 2 ........................................................................................................................ 52 
3.5.3 Paper 3 ........................................................................................................................ 53 
3.5.4 Paper 4 ........................................................................................................................ 53 
3.6 STATISTICAL ANALYSIS .......................................................................................................... 54 
4. RESULTS .................................................................................................................................. 56 
4.1.1 Paper 1 ........................................................................................................................ 56 
4.1.2 Paper 2 ........................................................................................................................ 56 
4.1.3 Paper 3 ........................................................................................................................ 56 
4.1.4 Paper 4 ........................................................................................................................ 57 
5. DISCUSSION ............................................................................................................................ 58 
5.1 METHODOLOGY ..................................................................................................................... 59 
5.2 THE EVALUATION OF DIRECT AND INDIRECT COSTS IN PD ..................................................... 61 
5.3 COST-EFFECTIVENESS IN THE TREATMENT OF PD .................................................................. 62 
5.4 FUTURE RESEARCH ................................................................................................................ 63 
6. CONCLUSION ......................................................................................................................... 65 
7. SOURCE OF DATA ................................................................................................................. 67 
 
 
 14
1. Introduction 
The intermingling of medicine and economy has been an issue for several thousand 
years. Asclepius, the god of medicine and healing in ancient Greek mythology, was 
stricken to death by Zeus with a thunderbolt because he raised the dead and accepted 
gold for it. Hippocrates of Kos (around 460 to 370 BC.) said: “We are allowed only 
to accept payment from those cured, when given out of gratitude, not something the 
patients promise when under great duress.”7, and as well in the Bible, Exodus 21.19, 
this question is discussed. Up to today the availability and fair distribution of medical 
help remains an issue of great and unsolved ethical significance, as its administration 
depends not only on the appropriate knowledge but as well on sufficient economic 
resources.  
Health economics is the branch of economics concerned with health and health care 
and the scarcity and allocation of resources within health care. Parkinson’s disease 
(PD) is a common neurodegenerative disease of the elderly, and its prevalence is 
expected to increase due to increasing live expectancy. The general part of this thesis 
will give a brief overview over the disease and over the field of health economics. 
Furthermore, this thesis intends to describe some aspects of the economic burden of 
PD as drug costs, institutional care, hospitalization and the cost-effectiveness of the 
disease management. 
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1.1 Parkinson’s disease 
1.1.1 Epidemiology  
Besides essential tremor Parkinson’s disease (PD) is the most common movement 
disorder, and next to Alzheimer’s disease the second most neurodegenerative 
disease1. In epidemiological research, the diagnosis of PD still relies on clinical 
criteria, as a definite diagnosis of PD requires post-mortem confirmation. The disease 
is found in all ethnic groups but with differences in prevalence8. Onset of sporadic 
PD in individuals under 50 years is only seen in 4% of the patients9. But both 
prevalence and incidence increases with age, and approximately 1-2% of the 
population over 65 years and 3-5% of those elder 85 years suffer from PD10. This 
indicates that about 0.5 to 1 million patients with PD are living in the European 
Union with approximately 500 million inhabitants11.  
Even if incidence studies are supposed to be more accurate as they are not influenced 
by mortality, reported incidence rates are showing substantial variance, probably due 
to methodological issues8. In the Western world, age-standardized incidence rates 
vary from 8.6 to 19.0 per 100 000 inhabitants12. Though results are contradicting and 
seem to differ with ethnicity, it is assumed that the incidence of PD is slightly higher 
in males8.  
 
1.1.2 Etiology and risk factors 
Until now the origin of the vast majority of idiopathic PD cases is unknown, and the 
strongest confirmed risk factor is advancing age13. Increasing evidence suggests that 
PD represents a common clinical feature of heterogenic causes14.  
In several epidemiological studies, relatives to patients with PD were found to have a 
3 to 4-fold increased risk for developing PD as compared to the general population15, 
16, and in approximately 10% of the cases a genetic cause is assumed. Until today 
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several gene mutations have been found, most of them causing juvenile or early onset 
PD, while others appear to cause parkinsonism resembling sporadic PD with respect 
to both clinical and demographical features8.  
A variety of non-genetic risk factors has been proposed. Most consistently, smoking 
is related to a reduced and exposure to pesticides to an increased risk for developing 
PD17, 18.  
 
1.1.3 Pathogenesis and pathophysiology 
Since the 1960’s it has been known that PD is caused by the degeneration of 
dopamine producing cells in the substantia nigra. Motor symptoms occur when 60 to 
80% of the cells are destroyed19, 20. Today, however, there is evidence that PD is a 
multi-system brain disease, involving as well serotonergic, adrenergic and 
cholinergic systems21. Braak and colleagues suggested a sequential development of 
the disease, starting in the brainstem and spreading via the midbrain and mesocortex 
to the cortex22, 23. Neurodegeneration is characterized by typical inclusions of 
aggregated α-synuclein, called Lewy-bodies. Braak proposed six stages, of which the 
first two represent pre-symptomatic stages and the last two severe disability and 
dementia. These changes appear to be due to oxidative stress, mitochondrial 
dysfunction and impairment of the ubiquitin-proteasome system. However, it is not 
yet clear how these pathways leading to premature cell apoptosis and clustering of 
intracellular α-synuclein are triggered24-26. 
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1.1.4 Clinical course and disease classification 
1.1.4.1 Motor symptoms 
PD is characterized by four so called “cardinal symptoms”: Tremor, bradykinesia, 
rigidity and postural instability. But not every patient has to present with every 
symptom. In idiopathic PD, symptoms normally start unilaterally and remain 
asymmetric during the whole course of the disease.  
Tremor is the most common motor symptom in PD and is present in 60 to 70% of 
the patients at disease onset27-29. The amplitude is variable and increases with anxiety 
or tension, while tremor disappears during sleep. Initially only a resting tremor, it 
may progress to postural and activity tremor, interfering with activities of daily living 
(ADL) and become a challenge to disease management. 
Bradykinesia describes a general slowness in movements, the difficulty to initiate 
movements and their decreased amplitude. This results in reduced facial expression 
and difficulties with alternating movements, progressing to gait inhibition with start 
hesitations and festinations and potentially severe impairment of ADL.  
Rigidity describes an elevated muscle tone, resulting in increased resistance when 
passively flexing or extending a joint. The so called “cogwheel phenomenon” is a 
combination of increased muscle tone and tremor. Clinically, rigidity leads to 
discomfort and aggravates the impairment caused by bradykinesia. Both bradykinesia 
and rigidity are the symptoms best accessible by medical treatment. 
Postural instability is seldom present in the early stages but develops over the 
course of the disease. Axial symptoms involve the typical stooped posture, but may 
as well lead to a posture leaning to one side. Postural alterations and decreased 
postural reflexes lead to propulsion and retropulsion with the impairment of gait and 
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an increased risk for falls. The successful management of rigidity and bradykinesia 
may as well improve postural instability. 
 
1.1.4.2 Non-motor symptoms 
As the motor symptoms in PD are quite dominant and – at least to a certain degree – 
treatable, non-motor symptoms often receive little attention. They are, however, 
present in close to 90% of all patients with PD and may severely affect the quality of 
life in both patients and caregivers30. They may develop during the course of the 
disease or even precede motor symptoms. Non-motor symptoms dominate the clinical 
picture of advanced PD and contribute to severe disability, reduced health-related 
quality of life (HR-QoL) and increased mortality31.  
Depression is common in PD. Prevalence figures differ widely, but an average of 25 
to 40% is assumed. The diagnosis of depression in PD might be challenging, as there 
is an overlap with other features like fatigue, apathy, and reduced spontaneous motor 
functioning. There are no specific characteristics of depression in PD as compared to 
the general population, but anxiety, dysphoria and irritability are reported more often, 
while self-blame tendencies, feelings of guilt and suicidality are reported less 
frequently32. 
Cognitive decline and dementia are among the most common non-motor changes in 
PD with an 80 % life-time risk of becoming demented33. Mild cognitive impairment 
occurs even in early PD and is associated with a shorter time span to develop 
dementia34. It is characterized by executive impairment, attention shift and 
visuospatial dysfunction35.  Other risk factors associated with dementia in PD are old 
age, disease duration, disease severity, and axial symptoms like postural instability or 
speech problems36-39.  
Hallucinations are most commonly visual hallucinations. They were previously 
considered as a side effect of the medical treatment of PD, but recent studies could 
not show any association between the development of hallucinations and the dosage 
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or duration of the treatment40, 41.  However, hallucinations are normally treated with a 
reduction in antiparkinsonian therapy and the elimination of drugs that are supposed 
to especially evoke psychosis like anticholinergics and dopamine agonists. In 
addition, atypical neuroleptics can help to control them. Hallucinations are an 
independent risk factor for admission s to nursing homes and can be experienced as 
very distressing by both patients and relatives. 
Fatigue is characterized by the subjective experience of a lack of energy, extreme 
tiredness and feeling of exhaustion after only small efforts. It can be both a physical 
and mental problem. Fatigue is not restrained to PD but can be seen in various 
neurological, psychiatric and systemic disorders. Even if there is overlap with other 
non-motor features like depression and apathy, it is assumed that as many as 
approximately 50% of the patients with PD experience fatigue42.  
Apathy describes a state of diminished motivation that leads to a reduction of 
initiative, flattening of affect or lack of emotional responses and lack of intellectual 
interest8. Until now there is little data published about apathy. A population–based 
cross-sectional study showed that apathy is common in the general PD population 
and may present as an independent behavioural disorder43. Apathy might be more 
often experienced as problematic by spouses than by the patients themselves. 
Sleep disorders: As PD involves the brainstem and communicating pathways in the 
ascending arousing system through the hypothalamus and thalamus to the cortex, 
sleep disorders are not uncommon. In addition, other symptoms like depression or 
motor impairment might contribute, and dopaminergic drugs, especially dopamine 
agonists are linked to different sleep complaints44, 45. Insomnia is the most frequent 
sleep disorder with a prevalence of 90% in a population-based cross-sectional 
study46. Excessive day time sleepiness (EDS) is reported in 15% in the same study 
population and has been shown to increase with disease duration47, 48 . Sudden sleep 
attacks have been linked to dopamine agonists49 . REM sleep behaviour disorder 
(RBD) is a parasomnia characterized by motor activity during REM sleep due to the 
loss of skeletal muscle atonia normally present during that sleep phase, leading to 
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vocalization and movements during the sleep, normally associated with dreams. 
Patients with RBD have an increased risk to develop PD and other α-
synocleinopathies like Multi system atrophy or Lewy-bodies disease, and up to one 
third of patients with PD are affected50, 51. Restless legs (RLS) and periodic limb 
movements during sleep (PLMS) are sleep disorders related to each other. There is 
evidence that these disorders are more common in patients with PD52, 53  
Autonomic disturbances: Symptoms like orthostatic hypotension, hypersalvation, 
urinary problems, constipation, sweating and sexual dysfunction are signs of 
autonomic dysfunction in PD of which the most frequent are constipation and urinary 
problems54. 
 
1.1.5 Diagnosis and differential diagnosis of PD 
Parkinsonism is a term describing a syndrome with the main motor features typical 
for PD (bradykinesia, rigor, tremor), despite its cause. Distinguishing idiopathic PD 
from other causes of Parkinsonism may be challenging, and even experienced 
neurologists fail28. Functional brain imaging using dopamine-ligands in single photon 
emission computed tomography (SPECT) or positron emission tomography (PET) 
may be used as supplementary diagnostic devices, but still in most patients the 
diagnosis is made according to the clinical symptoms and the effect of dopaminergic 
treatment. The use of strict diagnostic criteria therefore helps to improve diagnostic 
accuracy55.  
The Stavanger PD diagnostic criteria differentiate between clinical definite, 
probable and possible PD56. 
Clinical definite idiopathic PD: Asymmetrical presentation and tremor. In addition at 
least one of the following symptoms: rigidity, bradykinesia or postural abnormality. 
Good or excellent response to dopaminergic agents. No atypical signs at disease 
onset and CT or MRI of the brain without major pathology. 
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Clinical probable idiopathic PD: Two of the four cardinal symptoms present and not 
more than one of the following atypical features: dementia or clinically relevant 
autonomic failure at disease onset, symmetrical disease presentation, moderate 
response to dopaminergic treatment, or other atypical signs or symptoms that indicate 
another parkinsonian disorder. 
Clinical possible idiopathic PD: At least two of the four cardinal symptoms and at 
least moderate response to dopaminergic treatment. Mild to moderate dementia and 
autonomic failure is allowed. 
According to the Gelb criteria, the definite diagnosis of PD can only be made post 
mortem, when a clinical probable PD is confirmed by histopathologic confirmation. 
Table 1.1 shows a grouping of clinical features suggestive and non-suggestive for PD 
while table 1.2 shows clinical diagnostic criteria for PD as proposed by D.J.Gelb57.  
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1.1.6 Disease management   
PD is still an incurable disease, and disease management aims at the alleviation of the 
symptoms, improvement of the quality of life, support of patients and caregivers and 
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- to a certain degree - reduction of disease progression. Management strategies 
include antiparkinsonian drugs, surgery, physiotherapy, and information. 
 
1.6.1 Drug treatment against motor symptoms 
Pharmacological treatment of PD became available during the 1960’s with the 
introduction of levodopa medication. Today, the gold standard of medical treatment 
in incident PD is levodopa in elderly patients, while younger patients start with a 
dopamine agonist. When the disease progresses and increasing the dosage either does 
not show satisfying effect or leads to side effects, a combination of levodopa, 
dopamine agonists or Catechol-O-methyltransferase (COMT) inhibitors are normally 
given. In addition, patients younger than 75 years often receive monoaminoxidase-B 
(MAO-B) inhibitors due to their assumed neuroprotective effect. 
As antiparkinsonian drugs are a main part of PD management and therewith have a 
considerable impact on treatment costs, their indications, side effects and history are 
outlined here.  
Anticholonergics 
Anticholinergics were the first drugs used for PD, from the beginning of the last 
century, as they adjust the imbalance between acetylcholine and dopamine in the 
striatum. They have a certain effect on tremor and they improve some autonomic 
symptoms like excessive sweating and salivation. However, their effect on PD-
symptoms is mild, while there are severe side effects, mainly hallucinations. 
Therefore, in today’s treatment these drugs are hardly used any more. 
Amantadine 
Amantadine has been known as flu medications since the 1930’s. For the use in PD it 
was approved by the FDA in 1969. Both its antiviral action and its antiparkinsonian 
effect are poorly understood, but amantadine is a weak NMDA receptor agonist and 
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an anticholinergic. Besides its use in improving motor symptoms in PD it has also 
been used to improve long term complications of PD treatment as fluctuations and 
dyskinesias. 
Levodopa 
Levodopa was introduced during the 1960’s; marking a turning point in the treatment 
of PD as it was the first effective drug for the disease. Levodopa is a precursor of 
dopamine and passes the blood-brain barrier. It is taken up by dopaminergic neurons 
and decarboxylated to dopamine, therewith compensating for the deficient dopamine 
production caused by degeneration of the substantia nigra. To prevent peripheral 
decarbocylation, levodopa is normally combined with either carbidopa or 
benserazide. Compared to other antiparkinsonian drugs levodopa has a favourable 
profile of side effect. However, long term use is associated with the development of 
fluctuations and dyskinesias, probably due to the pulsative stimulation of the 
dopamine receptors. In advanced stages of the disease the continuous application of 
levodopa via a trans-abdominal tube is possible. Despite of the development of 
several new drugs, levodopa has remained the most important antiparkinsonian drug 
until today. 
MAO-B inhibotors 
Selegiline was discovered by Jozsef Knoll in the 1950’s and introduced to the drug 
management of PD in the late 1970’s. It acts as a MAO-B inhibitor and therewith 
inhibits the degradation of dopamine in the striatum. Besides a mild antiparkinsonian 
effect several studies have shown that the use of selegiline reduces progression in PD 
and thus might have a neuroprotective effect, but until today the results have not been 
conclusive. Recently, selegiline has as well been used as antidepressant, and it has 
been promoted as an anti-aging drug. Today, rasagiline is the newest 
antiparkinsonian drug on the market. It is a MAO-B inhibitor and is promoted to have 
a decreasing effect on the progression of PD.  
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Dopamine agonists 
Dopamine agonists directly stimulate the postsynaptic dopamine receptors. As a first 
short lasting agonist bromocriptine was introduced to the market in the 1970’s, 
shortly after followed by lisuride and alpha-dihydroergotamine, all with a half-life 
period of three to five hours. In the 1980’s pergolide was the first long acting agonist 
with a half-life period of approximately eight hours. During the 1990’s cabergoline 
with a half-live period of 72 hours came to the market. At the same time the first non-
ergot derivates were introduced, pramipexole and ropinirole, while rotigotine was 
the first transdermal application. Apomorfin is the only dopamine agonists for 
parenteral use. It can be applied subcutaneously either continuously in patients with 
severe motor complications or as a “rescue drug” to alleviate severe off-states. 
Dopamine agonist can be used as monotherapy for PD, or in combination with other 
antiparkinsonian drugs, mainly levodopa, to enhance effect while avoiding side 
effects due to high dosages. Especially the longer acting agonists improved 
therapeutic options, as they offer a more constant stimulation of the dopamine 
receptors, thus being less inclined to cause fluctuations and dyskinesias. Most 
dopamine agonists are ergotamine derivates with a number of unfavourable side 
effects, of which fibrosis of the lungs and heart valves is the most severe. Therefore, 
non-ergot derivates as pramipexole, ropinirole and rotigotine are normally preferred 
nowadays. 
COMT-inhibitors 
COMT inhibitors prolong and enhance the effect of levodopa by inhibiting its 
conversion into 3-O-methyl-levodopa. As a first COMT inhibitor tolcapone was 
introduced during the 1990’s, offering a new treatment option for patients with 
fluctuations. Due to some cases of fatal liver failure the drug was withdrawn from the 
market and its place was taken by entacapone. Entacapone has the inconvenience 
that it has to be taken together with every dosage of levodopa. A fast combination of 
levodopa, carbidopa and entacapone has therefore been developed. Due to the 
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enhanced effect of levodopa, dyskinesias are a frequent side effect and a challenge 
for drug management. 
Drugs against tremor 
Budipin is one of the few drugs that show a special effect on parkinsonian tremor. 
The substance has been known for some decades, but there has been doubt about the 
quality of the documentation of efficacy and safety. Arrhythmia of the heart is a 
severe side effect and limits the use of budipin.  Clozapine is an atypical neuroleptic. 
It is as well effective in the treatment of parkinsonian tremor. One severe side effect 
is leukopenia. Especially during the first months of treatment thorough monitoring of 
the leukocyte level is therefore mandatory. For the treatment of psychosis in PD other 
atypical neuroleptics are therefore preferred. 
 
1.6.2 Surgery 
Surgical treatment of severe cases of PD had its first peak during the 1970’s. In most 
cases a lesion in the ventral intermediate nucleus of the thalamus (VIM) was created 
in order to reduce tremor. Alternatively, a lesion in the globus pallidus interna (GPi) 
reduces dyskinesia. The definitive destruction of brain structures was problematic in 
less successful cases, and as medical treatment improved at the same time, surgical 
treatment was hardly used during the 1980’s. First towards the end of the last century 
surgical treatment became more prevalent again with the introduction of reversible 
deep brain stimulation (DBS). Uni- or bilateral an electrode is placed in the nucleus 
subthalamicus (STN), VIM or GPi, and electric pulses induce a functional 
impairment in this brain region. Patients who potentially benefit from the treatment 
are those suffering from untreatable tremor or patients with severe fluctuations and 
dyskinesias that cannot be controlled medically. Eligible patients should have a good 
to excellent levodopa responsiveness, should not be older than 70 years and have no 
history of severe mental illness.  
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1.6.3 Physiotherapy 
Until now it could not be proven that physiotherapy is effective in the management of 
PD. However, the clinical understanding is that physical activity is helpful in 
maintaining a good health state. Patients with PD have a reduced rotation of the spine 
while moving. They may as well have difficulties learning new movement sequences 
and have a disturbed balance. Young and active patients do not need guided training, 
whereas patients in more advanced stages will profit from physiotherapy that 
addresses these problems. 
 
1.1.7 Prognosis  
PD is a chronic and progressive disease and until today not curable. The rate of 
progression shows a great interindividual variation. Even if PD is not a fatal disease, 
both mortality and morbidity are increased58. Hoehn and Yahr reported a 
standardized mortality ratio (SMR) of 2.92, while a population based study of 245 
patients in 2004 reported a SMR of 1,52 after 8 years of follow up59. 
In clinic-based studies, approximately 40% of patients developed motor problems 
within four to six years after disease onset60, while over 78% of the patients in a 
community-based study did not experience motor fluctuations after over 6 years of 
levodopa treatment61. 
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1.2 Health economics 
(Sources: 62-65)  
Economics are divided into micro- and macroeconomics, where macroeconomics 
look at the performance, structure and behaviour of a nation or region as a whole, 
while microeconomics study how individuals, households or firms make decisions in 
allocating scarce resources.  
Health economics is a branch of economics concerned with health and health care 
and the scarcity and allocation of resources within health care. Its origin is dated to 
1963, when Kenneth Arrow published an article that outlined the factors 
distinguishing health economics from “other” economics in a free market 66.   
In a free market without any government intervention or regulation and without 
private fraud or force, property rights are exchanged at prices based on the mutual 
consent of buyers and sellers. Provided free competition, prices are a consequence of 
supply and demand. In theory, a free market will be the most effective of markets. 
Health care services do normally not meet the requirements of a free market. 
Governments tend to regulate the health care industry heavily, and they often bear the 
biggest burden of it. There is an information asymmetry between physicians and 
patients, and there is uncertainty related to health, treatment costs and treatment 
outcomes. In addition, effectiveness might not be the only concern when providing 
health care, but other factors like equity, accessibility and externalities may as well 
be important.  
Alan Williams divided the discipline of health economics into eight distinct topics as 
shown in his “Plumbing diagram” in figure 1.1 67. 
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Figure 1.1: Alan William’s “plumbing diagram” (1987) 
 
1.2.1 What influences health (other than health care)? (A) 
In 1974, the Lalonde report suggested that there were four determinants of health, 
including human biology, environment, lifestyle and health care organization 68. This 
point of view is as well represented in the definition of health by the World Health 
Organization 69.  
An example for health improvements that can not be attributed to health care services 
is the decline in population mortality rates in Europe after 1750 due to reduced 
exposure to infection by better water quality and sewage systems and the sanitary 
handling and treatment of foodstuffs (McKeown, p.121)70.  
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1.2.2 What is health? (B) 
In 1948, the WHO defined health as “a state of complete physical, mental, and social 
well-being and not merely the absence of disease or infirmity.”69 Though this 
definition is cited a lot, most people will settle for a less ambitious one. However, the 
definition emphasizes that health is not only an individual condition but is as well 
closely interrelated to the individual’s living conditions. 
 
1.2.3 Health care demand (C) 
The demand for health care is really a demand for health. According to Michael 
Grossman, health can be seen as a stock of health capital, and health care is one mean 
to enlarge this stock or, in other words, produce health71. Another mean is investing 
time devoted to health-improving efforts like physical exercise. Health will last for a 
long period and does not depreciate instantly. It can therefore be considered as a 
capital. At the same time, health can be treated as both an investment good and 
consumption good. As consumption good it improves well-being. As an investment 
good it increases the number of healthy days and therewith the availability to work 
and earn money. In Grossman’s model, the optimal level of investment in health 
occurs where the marginal costs of health capital are equal to the marginal benefit. As 
health depreciates over time, it becomes more and more costly to attain the same 
level of health as one ages while the marginal benefit decreases with age. As a result, 
the optimal health stock decreases as one ages.  
Health care demand responds at least to some extend to microeconomic principles of 
supply and demand. When prices are high, the demand is low. But when prices 
decrease, the demand will increase. A typical example for that situation is health 
insurance. The higher consumption of health care services by insured individuals 
versus non insured individuals is called moral hazard. 
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1.2.4 The supply of health care (D) 
Besides providing health, the health care system is as well operating as a large 
marked for work forces. In Norway, there are 31.6 nurses per 1000 inhabitants, far 
above the average of 9.7 practising nurses per 1000 inhabitants within the 
organization for economic co-operation and development72. In theory, the labour 
marked is controlled by the same mechanisms of demand and supply as other goods. 
The supply of work forces will thus increase with increasing wages and vice versa. 
There will as well be options for substituting various factors with each other, like for 
example technicians with radiologists or manpower with technical equipment. In 
general, it will seem more profitable to hire personnel with lower education for lower 
wages. On the other hand, higher educated personnel will be able to perform a larger 
number of different tasks, therewith enhancing the organization’s elasticity in 
responding to different demands. 
 
1.2.5 Micro-economic evaluation at treatment level (E) 
“Economic evaluation is the comparison of two or more alternative courses of action 
in terms of both their costs and their consequences.” (Drummond, p.9 62) There are 
several types of evaluation, differing in how consequences are measured. The exact 
terms are not fixed and may differ from country to country. The following types of 
evaluation are of interest: Cost-consequences analysis, cost-minimisation analysis, 
cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis. 
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1.2.5.1 Cost-consequences analysis 
A cost consequences analysis is not necessarily a comparison between to options but 
rather a description of the costs of a certain action and the consequences this action 
results in. As, for example, the costs for hip replacement and different outcomes after 
surgery. Also “burden of illness analysis” belongs to this category. 
As for other economic evaluations, the question of which costs and which 
consequences to include into the analysis has to be answered. As for the hip 
replacement, one could include only costs for surgery, or include as well costs for 
hospital stay, costs for rehabilitation, costs that are saved because of a gain in 
independency etc. This example illustrates as well the need to determine the 
perspective out of which the evaluation will be taken. The department of surgery 
might only be interested in surgery costs, whereas the hospital will include all costs 
arising during the stay, and the health care system will as well take rehabilitation into 
account. A societal perspective might as well be interested in the need for care in the 
future. 
Costs of illness analyses describe the economic burden of a disease. According to 
DP. Rice, the costs for a disease are divided into direct and indirect costs73. Direct 
costs are subdivided into direct medical costs as drugs, hospital stays, rehabilitation, 
transport, and physician consultations, while direct non-medical costs derive from the 
need for care. Indirect costs are caused by the foregone opportunity to work due to 
reduced productivity or death. 
1.2.5.2 Cost-minimisation analysis 
As a requirement to a cost minimisation analysis the outcome of two different 
interventions must be proven to be equal. By evaluating the costs for each 
intervention, one will aim to determine the cheapest. As well in this kind of 
evaluation the result might depend on the choice of costs to be included. The time 
horizon, for example, may play a major role, as only present or also future costs 
could be integrated. 
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1.2.5.3 Cost-effectiveness analysis (CEA) 
The requirements for a CEA are the complete evaluation of both the costs (input) and 
the consequences (output) of two or more intervention alternatives. In contrast to a 
cost minimisation analysis, the outcomes of the interventions might be different. The 
cost-effectiveness plane as shown in figure 1.2 illustrates the four possibilities of 
outcome in an evaluation with two treatment arms (whereof one treatment arm could 
as well represent “doing nothing”).  
 
 
Figure 1.2: Cost-effectiveness plane (From: John Cairns: Tuition material, “Course in 
Health economics”, Health economics Bergen, 2007) 
 
The choice of which arm to prefer seems simple when one treatment arm is either 
both more costly and less effective (north-western quadrant) or more effective and 
less costly (south-eastern quadrant). Clearly preferable options are therefore called 
“dominant options”. 
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However, in many cases the new treatment might prove as more costly and more 
effective at the same time. In these cases, an incremental cost-effectiveness ratio 
(ICER) will provide additional information. The ICER evaluates the price per unit of 
output, as for example lives saved, cancer cases detected, or points on any given 
scoring scale.  
1.2.5.4 Cost-utility analysis (CUA) 
In a CEA interventions can be compared to each other as long as the outcomes can be 
measured in the same unit. In a CUA the outcome measurement is converted to a 
universal unit which is called Quality adjusted life years (QALYs). Strictly speaking, 
the CUA is thus a special case of CEA. The concept of QALYs will be discussed 
later in more detail. 
1.2.5.5 Cost benefit analysis (CBA) 
In a CBA both the input and the output are measured in monetary terms, as for 
example the costs of an intervention and the savings due to avoided days of sick 
leave. The result can be expressed as a monetary net benefit or loss, or as the benefit-
cost ratio. A CBA allows for the decision whether a programme pays for itself. On 
the other hand, not all health benefits can be captured in monetary terms, and a CBA 
may therefore be a supplementary evaluation to a CEA or CUA. 
 
1.2.6 Market equilibrium (F) 
Health care systems may function as free markets, but in many countries the state 
heavily regulates the health care industry. Within the healthcare system, private and 
public players may be active, both as health care providers and as health insurances. 
In the US, for example, the majority of the market is private while in Norway almost 
the entire health sector is run by the state or the municipalities. 
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In Norway, public health insurance is mandatory and a part of the tax payments, thus 
providing a nation wide risk pool. On the other hand, the unexceptionally public 
market of health care providers does not have to face any competition, and 
effectiveness has therefore been an issue in Norwegian health care services. Since 
2002 all hospitals have become state run, and various incentives to improve 
effectiveness have been established. One example is the shift from a “Fee for service” 
reimbursement system to a production dependent system based on diagnosis-related 
groups (DRG), where the hospital is partly refunded based on the number of patients 
treated and the statistical use of resources according to the patients’ diagnoses. 
Licensures and authorisations are instruments to ensure quality of care. At the same 
time, they are as well an instrument of controlling competition by younger colleagues 
or immigrants. In Norway not only the number of specialized physicians working in 
hospitals is regulated, but as well the number of trainees for each specialty. This 
regulation is meant to ensure the quality of education, but may at the same time 
prevent an overproduction of specialists or even create an artificial shortage. 
1.2.7 Evaluation at whole system level (G)     - 
equity versus effectiveness 
When evaluating health care systems by measuring the amount of QALYs that is 
“produced” by interventions, the best results would be achieved by treating 
individuals who are easily accessible and respond well, namely the rich and well 
educated. Seen from a societal perspective this might be less effective, because the 
overall health within a population might decline. It is as well in contrast to the 
general perception of fairness. 
Nobel laureate Amartya Sen stated in the essay “Why health equity?” that equity in 
health was part of social equity and justice74. “Health equity cannot be concerned 
only with health, seen in isolation. Rather it must come to grips with the larger issue 
of fairness and justice in social arrangements, including economic allocations, paying 
appropriate attention to the role of health in human life and freedom.” (p.659) In the 
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same way as Lalonde (1974) or the WHO, Sen emphasizes the social aspect in 
achieving and maintaining health, saying that health equity cannot merely be 
understood in terms of the distribution of health care, but must take into account how 
resource allocation and social arrangements link health with other features of state 
affairs. “Health and survival are central to the understanding not only of the quality 
of one’s life, but also for one’s ability to do what one has reason to want to do. The 
relevance of health equity for social justice in general is hard to overstress.” (p.663) 
Allan Williams presented in 1997 the concept of “fair innings”, proposing that 
everyone is entitled to a normal span of life at a reasonable quality of life75. He 
suggests that individuals that have had their share of good years (approximately 60 
QALYs) should step back when scarce resources are allocated. However, Williams’ 
concept has been criticized for being a too simple approach to health equity. 
 
1.2.8 Planning, budgeting and monitoring mechanisms (H) 
As budgets within the health care sector are limited, there is the necessity to set 
priorities. To make informed choices, decision makers depend on tools that help to 
judge the social value of medical interventions.  
Erik Nord76 showed in a review of the guidelines for priority setting in health care in 
several Western countries that these guidelines converged in the following points: 
A: Society demands that medical interventions satisfy a minimum requirement of 
effectiveness. 
B: Society’s appreciation of medical interventions increases strongly with increasing 
severity of the patient’s condition. 
C: Life saving or life extending procedures are particularly highly valued. 
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D: When a minimum requirement of effectiveness is satisfied, society worries less 
about differences in the size of the health benefits provided by treatment programs 
for different patient groups. 
E: Society in most cases does not wish to discriminate between people with different 
potentials for health in decisions about life saving or life extension. 
Weighing the social value of health programmes in terms of QALYs gained would 
not satisfy the requirement of social fairness and justice, as this method does not take 
disease severity into consideration (point B) nor does it distinguish between life 
saving interventions and those that improve the quality of life (point C). 
Bleichrodt et al. therefore developed the Rank-dependent QALY model77. In this 
model patient groups are ranked according to the severity of their state. The worst-off 
group will get the highest equity weight assigned to, and therewith most resources, as 
this is the group the society or policy makers are most concerned of. Then the next-
worse group and so on. The model is not sensitive to the magnitude of differences 
between groups but only to the ranking. 
Cost-value analysis provides another numerical modelling of social valuation, where 
concerns of fairness and effectiveness are taken into consideration78. In a set of eight 
health states between healthy and dead, one step up the scale is valued more highly 
the lower the start point, and the marginal value decreases significantly with 
increasing treatment effect. This approach compresses several different aspects in 
health care: initial severity, potential for improvement and the actual health gain.  
       
1.2.9 Quality adjusted life year (QALY) 
The terms “utility”, “value” and “preference” are often used interchangeable, while 
“preferences” actually is an umbrella term for both “utility” and “value”. Strictly 
speaking, values are obtained by measuring outcome preferences under certainty, 
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while utilities are obtained by measuring outcome preferences under uncertainty. 
However, we will only use the term “utility” in the following.  
In economics, “utility” describes the satisfaction from or desirability of the 
consumption of goods. In health economics, “utility” expresses preference-based 
measures of health.  
QALY is a unit for measuring utility in health economics. Mathematically, the 
amount of QALYs can be expressed by the equation: 
 QALYs = utility score  x  time. 
 
As shown in figure 1.3, the amount of QALYs is the area under the curve with time 
on the horizontal axis and utility scores on the vertical axis. The concept thus 
combines the health state with the duration of life. In the diagram, the individual will 
without intervention have a lower HR-QoL and a shorter time of survival, obtaining 
q1 QALYs, while the intervention leads to a higher HR-QoL and longer time of 
survival, obtaining q2 QALYs. The net gain in QALYs will thus be q2 – q1. 
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Figure 1.3: QALYs gained from interventions (From: Drummond: Methods for the 
Economic Evaluation of Health Care Programmes.62) 
 
Utility scores are a measurement for health state preferences. That means a ranking of 
different health states according to the abstract and subjective imagination of which 
state an individual would prefer to another. The question is asked to a large group of 
individuals, thus getting a statistical mean. Utility scores rank from 0 to 1, where 0 
represents death and 1 perfect health. All other states are assigned weights between 0 
and 1. However, some systems allow as well for weights below zero, indicating that 
there are states worse than death. There are several methods for measuring 
preferences for health outcomes and thus determining utility scores: The time trade-
off 79, the visual analogue scale (VAS), and the standard gamble (SG), where the 
TTO and VAS represent measurements under certainty and the SG measurement 
under uncertainty. 
- TTO: The respondents have to choose between a certain period of time in a 
state of ill health and a shorter period of time in perfect health. 
- VAS: The respondents have to place various states of health on a scale from 0 
= death to 100 = perfect health. 
- SG: The respondents have to gamble between remaining in a state of reduced 
health for a certain period of time and a medical intervention with the chance 
of either being restored to full health or dying. 
Preferences for health outcomes are specific for the cultural context of the 
respondent. Therefore, scoring systems may not be transferred from one country to 
another without adjustments in validation. In addition, respondents do normally not 
suffer from the affliction in question, as afflicted individuals on average assign a 
higher HR-QoL to the state. 
As measuring preferences for health outcomes normally are a difficult and time 
consuming task, questionnaires have been developed to bypass these measurements. 
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There are several pre-scored multi-attribute health status classification systems. We 
will present two of the most widely used: The EQ5D and the SF-6D.   
- EQ5D: This system was developed by the Western Europe EuroQoL group. It 
contains the five dimensions mobility, self-care, usual activity, 
pain/discomfort, and anxiety/depression. Each dimension has three levels: No 
problems, some problems, and major problems. The EQ5D allows for scores 
below zero ranking from -0.4 to 1 80. The EQ5D was validated by the 
preferences for health outcomes of about 3000 individuals in the UK. 
- SF-6D: This systems was derived from the health status questionnaire, the 
Short form 36 (SF-36) 6. The SF-36 is widely used, and the SF-6D provides an 
instrument for converting these data into utility scores. The instrument 
contains six dimensions: Physical functioning, role limitation, social 
functioning, pain, mental health, and vitality, each with four to six levels. The 
instrument was as well validated in the UK. Next to death, the lowest weight is 
0.3. 
 
As mentioned above does the concept of QALYs have the advantage of combining 
life expectancy with the health state. At the same time, the concept is easy to 
understand as well for non-economists. It has therefore become a popular tool for the 
allocation of health care resources. In the U.K, for example, there is an official cut-
off for cost-effectiveness at a price of £ 30 000 per QALY. In Norway, there is an 
unofficial cut-off at NOK 600 000. 
However, the QALY concept has been criticized as a too narrow measurement of 
benefits. It does not capture the quality of care, or the gain that lies in reassurance 
and information, nor does it capture any benefits to the patient’s family or care 
givers. Other critics include the unreliability of the measurements, as the various 
methods can produce diverging outcomes. In addition, the fact that there are various 
questionnaires used to obtain utility scores diminishes the comparability of the 
results81.  
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1.2.10 Disease adjusted life year (DALY)  
The WHO developed the concept of DALY for measuring the burden of disease. It is 
designed for measuring the combined impact of premature death and disability, thus 
evaluating DALYs lost due to disease. The scoring spans from 0 = full health to 1 = 
death, and the scores are not evaluated by interviewing amateurs but determined by 
an expert panel. Japanese life expectancy is used as reference for premature death as 
Japan is the nation with the world’s highest life expectancy. DALYs for individuals 
in the productive age get an extra weighting as they potentially provide for families. 
The concept of DALYs has been criticized for overrating the burden of disease, 
mainly because life expectancy is not adjusted to local conditions. 
 42
 
1.3 The economic burden of PD 
The burden of a disease is described by its economic impact and its effect on the 
quality of life of the afflicted and his family. During the last two decades there has 
been an increasing interest in the burden of diseases. The world’s population is not 
only growing in number but as well getting older. Population projections forecast an 
increasingly unfavourable ratio between the share of elderly and those who 
potentially can take care of them. The prevalence of diseases typically for old age 
will increase, as for example dementia, cancer, cardiovascular diseases, and of course 
PD. Besides the direct medical costs, the increasing need for formal and informal care 
will cause high non-medical costs and a rising demand for adequately trained 
caregivers. In addition to providing useful information for health care 
administrations, the evaluation of the burden of disease might as well help to identify 
cost driving factors and form the basis for further evaluations of treatment efficacy 
and efficiency. As one expects health to detoriate with advancing age, the burden of a 
disease should be related to the burden of morbidity in a population with a 
comparable age and sex structure or to the burden of other diseases typical for the 
same age group (like PD to cardiovascular diseases or dementia). 
The WHO’s study about the global burden of neurological disorders gives an 
estimate for 2005 and projections up to 2030, using a top-down approach82.  
According to this study, PD is responsible for 0.11% of all DALYs world wide today, 
and this number will rise slightly to 0.13 in 2030. However, in highly developed 
countries the amount of DALYs due to PD is almost 3-fold higher than for the 
average world population with 70.8 versus 25.1 per 100 000 population. 
Most other studies on the burden of PD use a bottom-up approach, some of them 
analyzing the total economic burden, some of them analyzing only certain aspects of 
the disease. Due to differences in patient samples and methods, the results are often 
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difficult to compare to each other, and there are few studies using control cohorts, 
thus evaluating the incremental costs caused by the disease. The following studies 
evaluate either direct costs or total costs caused by PD: 
 
Studies without control cohort: 
- Whetten-Goldstein et al. (1997)83 evaluated the costs to society of 109 patients with 
PD in a cross-sectional study in the US, finding total costs of $US 6115 per year. 
Earning loss of those less than age 65 was the greatest single element. Spouses 
providing informal care did so at mean 22 hours a week. 
- Dodel et al. (1998)84 evaluated the costs of 40 patients with PD over a three months’ 
period in Germany, finding direct costs of $US 3390 ($US 13 560 per 12 months). 
Costs driving factors were disease severity and fluctuations. 
- LePen et al. (1999)85 followed 294 French patients with PD over a period of six 
months, evaluating both direct and indirect costs. He found mean costs of Euro 2358 
over this period, with hospitalization being responsible for 39% of the costs. The 
main cost predictor was disease severity.  
- Hagell et al. (2002)86 followed 127 Swedish patients with PD over one year, 
evaluating both direct and indirect costs. He found annual costs of Euro 8000, of 
which 60% counted for indirect costs due to loss of production. 
- Findley et al. (2003)87 conducted a cross-sectional study of 444 patients with PD in 
the UK evaluating the direct costs caused by the disease. They found mean annual 
costs of £ 5993 per patient. Cost driving factors were independency in daily living, 
disease severity, quality of life and institutional care. 
- Kerænen et al (2003)88 conducted a study of 260 patients attending neurological 
outpatient clinics in Finland. He calculated costs from a societal point of view, 
finding that mean total costs were Euro 11 800 per patients of which the direct costs 
caused 41% and early retirement 43%. Of the direct costs hospitalization was the 
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biggest cost-driving factor accounting for 41%. Costs were related to disease severity 
and inversely to the quality of life. Patients in need for institutional care were not 
included. 
- Spottke et al. (2005)89 conducted a prospective study over six months with 145 
patients, taking the perspective of the German public health care system. They found 
total costs of Euro 6560 with direct costs accounting for 51% and indirect costs for 
49%. Cost driving factors were disease severity and reduced quality of life. As the 
study was conducted from the perspective of the public health insurance, costs for 
home care or nursing homes were not included. 
- Mc Crone et al. (2007)90 followed 175 patients with PD for one year in the UK. 
Direct medical and non-medical costs were included, though no patients were in need 
for institutional care. Mean costs per patient and year were £ 13 804, with 80% of the 
costs caused by informal care. Cost driving factors were male sex, depression and 
disability. The authors equalled costs for informal care with costs for formal care. 
 
Studies using control cohorts: 
- Rubenstein et al. (1997)91 compared 43 patients with PD to a 3-fold larger matched 
cohort in the US, following them over one year. Patients with PD used more health 
care resources and caused $US 10 168 during that year, while controls caused a mean 
of $US 4743. Only direct medical costs were included. 
- Guttman et al. (2003)92followed a cohort of 15 304 Canadian patients with PD and 
30 608 matched controls over six years. He found that patients with PD had a higher 
use of health care resources, but the total incremental costs per year and patient are 
not specified in the paper. 
- Huse et al. (2005)93 evaluated data from health insurance claims of 20 016 patients 
with PD and an equally sized control group in the US during a follow up of a mean of 
2 ½ years. Incremental direct costs for patients with PD were $US 10 349 per year. 
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- Noyes et al. (2006)94 evaluated the health care utilization and expenditures of 
Medicare subscribers in the US between 1992 and 2000, finding incremental annual 
direct costs of $US 7710 for patients with PD and a higher need for home and 
institutional care. 
- Leibson et al. (2006)95 followed a cohort of 92 patients with PD and 92 controls 
over a period of 11 years in a population-based prospective study from the US. They 
found that there were no statistically significant incremental costs during the first five 
years after diagnosis, but that patients with PD caused incremental costs of $US 1146 
per year during the last five years. The study included direct medical costs except 
out-of-pocket payments. 
 
Summing up the results of the presented studies, there is a general agreement that 
the burden of PD is considerable. Patients with PD have a high use of health care 
resources and induce significant costs. Direct costs range from $US 1750 to $US 
17 560 (2002 prices)93. Studies using insurance claims as data source report lower 
costs, possibly because they only reflect all costs. Of the four studies evaluating the 
incremental costs of PD, three report direct incremental costs between $US 7700 and 
$US 10 300 and one reports much lower costs of $US 1022 (2002 prices). Cost 
driving factors are disease severity, reduced quality of life, reduced independence in 
ADL, motor fluctuation, institutional care, and depression. In studies evaluating both 
direct and indirect costs, loss of production accounts for as much as 43% to 60% of 
the total costs, though only a minority of the patients is aged younger than 65. 
Unfortunately, none of the controlled studies evaluated indirect costs.  
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2. Aims of the study 
The primary objective of this study was to achieve a better understanding of the 
economic burden of PD to society. To obtain that information we have: 
 
I. compared the costs for antiparkinsonian drugs in a German and Norwegian 
cohort of patients with PD and evaluated the use of antiparkinsonian drugs 
in relation to disease severity, disease duration and national prescription 
habits (paper1). 
II. examined the risk for living permanently in a nursing home for patients 
with PD as compared to age- and sex-matched individuals from the general 
population and calculated the costs related to long-term nursing home care 
in Norway (paper 2). 
III. evaluated the possible incremental costs of hospitalization in PD as 
compared to the general population, and examined the distribution of 
diseases causing hospital admissions (paper 3). 
IV. evaluated the health states of newly diagnosed patients with PD as 
compared to age- and sex-matched controls  and calculated the incremental 
cost-effectiveness ratio (ICER) during the first year of drug treatment 
(paper 4). 
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3. Methods 
3.1 Study design 
3.1.1 Paper 1 
Cross-sectional study. 
3.1.2 Paper 2 
Cross-sectional prevalence study at baseline and prospective longitudinal cohort 
study over a 12-year study period. 
3.1.3 Paper 3 
Prospective longitudinal cohort study over a 12-year study period. 
3.1.4 Paper 4 
Prospective longitudinal cohort study over a 1-year study period of patients with 
newly diagnosed PD. 
3.2 Patient selection 
3.2.1 Paper 1 
The German cohort consisted of 286 consecutive patients with PD seeking advice at a 
PD counselling project and who were taking medication for the disease. In addition, 
they had to be able to give reliable information about their medical history and drug 
use. The counselling project was a free-of-charge offer for patients and their relatives 
 48
in the Rhein-Main area, Germany, that included advice in different aspects of the 
disease as disease management, diagnosis, coping and social problems. It did not 
include active disease management or drug prescriptions, and the patients were 
normally followed by outpatient clinics for movement disorders, neurologists in 
private practice, or general physicians. All patients included in the cohort were 
examined personally. The data were collected at the first contact with the patient 
during a 12-month period from March 1st 1998 to February 28th 1999. 
The Norwegian cohort was drawn from the outpatient clinic of the Department of 
Neurology at the Stavanger University Hospital, Norway in the year 2001. 
Information on the patients was collected retrospectively from the hospital’s medical 
files. 152 patients were included who had the clinical diagnosis of PD and used 
antiparkinsonian drugs, and where reliable data about disease duration, disease 
severity according to HY stage, and drug use could be obtained. To avoid bias 
between the two cohorts, patients visited in nursing homes were not included. As 
both COMT-inhibitors and the newer dopamine agonists came to the Norwegian 
market about two years later than to the German market, we chose to collect data in 
the year 2001 to have a comparable availability of drugs. 
3.2.2 Paper 2 and 3 
Between September 1992 and May 1993, a population-based prevalence study was 
conducted in Rogaland County, Western Norway 96. To achieve complete case 
ascertainment, information from all relevant sources was obtained, as hospital files, 
general practitioners, nursing homes, district nurses, health workers and the Rogaland 
Parkinson’s Disease Society. Of about 400 patients examined by neurologist with a 
special interest in movement disorders 245 were diagnosed with PD according to 
published diagnostic criteria 56, and 239 patients were able and willing to participate 
in the study. These patients have been followed in a longitudinal study later on, with 
clinical examinations in 1993, 1997, 2001 and annual clinical examinations from 
2002 and up to today.  
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We used a subset of this patient population, including only the 108 patients who were 
living in the municipality of Stavanger in 1993. The municipality of Stavanger is the 
largest municipality in the area and provides complete and digitalized information 
about municipal services as long back as November 1993, while it was not possible 
to obtain reliable information in the other municipalities. The cohort of patients with 
PD was followed over a 12-year period from January 1st 1993 to December 31st 2004. 
3.2.3 Paper 4 
The Norwegian ParkWest study is a prospective longitudinal cohort study of patients 
with incident PD from Western and Southern Norway. The study area comprises a 
population of about 1 million inhabitants. During the period between November 1st 
2004 and August 31st 2006 one sought to include all residents with incident PD in the 
study area. Patients who were diagnosed with possible or probable PD according to 
published diagnostic criteria57 at the screening examination and who consented in 
participating in the study underwent baseline examination and have been followed 
since with clinical examinations at least twice a year and an additional consultation 
four weeks after the start of PD-medication. Patients that developed dementia during 
the first year of motor onset were excluded97. The Norwegian ParkWest study 
includes 212 patients. We excluded patients that were not drug-naïve at baseline or 
where information about the health status was incomplete. Four patients dropped out 
because of death. Our patient cohort consisted thus of 199 patients with newly-
diagnosed PD. 
3.3 Control subjects 
3.3.1 Paper 2 and 3 
Through the National registry we identified eight control subjects for each patient 
with PD who matched in sex and age and were living in Stavanger on January 1st 
1994. The National registry is a government registration agency where each 
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Norwegian citizen is registered with name, address and an 11-digit social insurance 
number coding for date of birth and sex. In addition, the eventual date of death is 
registered. For the control cohort we had to delay the study period by one year, 
because it was too difficult to extract data from the National registry in 1993. In 
addition, there was no reliable data about long term nursing home admissions 
available before November 1993. Control individuals were therefore followed from 
January 1st 1994 to December 31st 2005. In paper 2 all 864 control individuals were 
included into the cross-sectional part of the study at baseline. Six individuals had to 
be excluded from the longitudinal part due to emigration from the study area during 
follow-up. In paper 3 four additional control individuals had to be excluded because 
according to the hospital files they had developed PD during the study period.   
3.3.2 Paper 4 
Among relatives and acquaintances of the patients of the ParkWest study 205 
controls were recruited. We included a subset of 175 control individuals who 
provided the best possible group match regarding sex, age and education. We had to 
exclude three control individuals where information about the health status was 
incomplete. The control cohort consisted thus of 172 individuals. 
 
3.4 Assessment of clinical data 
3.4.1 Paper 1 
For the German cohort, data was collected personally at the first consultation of the 
patient during the study period. Data about age, sex, disease duration and history was 
obtained in addition to present drug use. Disease severity as measured by Hoehn and 
Yahr (HY) stage2 was determined by history and clinical examination. 
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For the Norwegian cohort, clinical and demographic data and information about drug 
use was collected retrospectively from the hospital files at the first consultation 
during the study period. 
3.4.2 Paper 2 
For patients with PD, clinical data about age, disease duration, disease severity as 
measured by HY stage and cognitive impairment as measured by Mini Mental State 
Examination (MMSE)3 were collected at baseline examination. Information about 
permanent admission to a nursing home was collected at the clinical examinations 
and by the municipality’s registration system for delivery of services “CosDoc” and 
“PLOMS”. The date of death was provided by the hospital files for patients with PD 
and the National registry for control individuals. 
3.4.3 Paper 3 
For patients with PD, clinical data about age, disease duration, and disease severity as 
measured by HY stage were collected at baseline examination. Data about hospital 
admissions, department of admission, length of stay and discharge diagnosis were 
obtained from the files of Stavanger University Hospital. As this is the only hospital 
within two hours of driving, we did not collect data from other hospitals. The 
discharge diagnoses were categorized as PD, vascular disorder, cancer, trauma, 
pulmonary disease excluding cancer, muscle/connective tissue disorders, diseases of 
the genitourinary tract, rehabilitation and other. 
3.4.4 Paper 4 
For the patients, information about their medical history including age and disease 
duration was collected at baseline. Information about disease severity and drug use 
was collected at every clinical consultation. Data about health status was collected at 
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baseline and after one year. For controls, data about health status and independence 
in ADL was collected at baseline and after one year. 
Disease severity was assessed by the Unified Parkinson’s Disease Rating Scale 
(UPDRS)4 including the modified HY staging. The health status was assessed by the 
Short form 36 questionnaire (SF-36)5 which was completed by both patients and 
controls at baseline and after one year.  To calculate utility scores, the data of the SF-
36 were converted to the Short Form-6D (SF-6D)6, 98. For controls, independence in 
ADL was measured by using the UPDRS part II. 
 
3.5 Assessments of costs 
3.5.1 Paper 1 
Drug costs were determined according to the price list from the German drug 
compendium “Die Rote Liste 1999”, the Norwegian drug compendium 
“Felleskatalog 2001” or the pharmacists’ price quotes. We included only drugs that 
were prescribed for the treatment of motor symptoms of PD. Costs were expressed in 
“Costs per patient per day”. 
3.5.2 Paper 2 
As each nursing home in Norway has its own economy and its own pricing, there are 
no official calculations of the costs for institutional care in Norway. We used prices 
as quoted by the accountant centre of the municipality of Stavanger as an estimation 
of costs for the year 2007. We verified these costs by comparing them to the costs 
quoted by the municipality of Bergen and Oslo. We calculated costs from the societal 
perspective and therefore included both costs refunded by social services and users’ 
fees. As it was not possible to obtain reliable information on costs for institutional 
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care as long back as 1993, we could not calculate the actual costs that emerged during 
the observation period. We therefore projected the costs to the year 2007 by 
evaluating the percentage of the time an individual spent in nursing home during the 
study period and multiplying it with the annual costs for institutional care. Costs were 
thus expressed in “Costs per person year of survival”. 
3.5.3 Paper 3 
In Norway all costs related to hospital admissions are borne by the National Health 
Service. We therefore assumed that these costs were the total costs emerging to 
society. Up to 2001 hospitals were refunded based on patient-days of in-hospital stay. 
Since 2001 refunding has been based on a combination of a fixed budget and a 
flexible refund based on the patients’ discharge diagnoses following the “diagnose 
related grouping” (DRG) system. Both systems do not reflect the patients’ real costs 
but operate under the assumption that some patients will cost more and some patients 
less than refunded, and that this will be levelled out when large numbers of patients 
are treated. We chose to calculate costs for in-hospital stay by an average price per 
day for the Stavanger University hospital as quoted by SAMDATA99 and the 
hospital’s accounting centre for the year 2005. We expressed costs as “Costs per 
patient per year of observation period” and “Costs per person year of survival”. 
3.5.4 Paper 4 
Costs related to medication for the treatment of PD motor symptoms and 
consultations at the outpatient clinics of Neurology were used as treatment costs, as 
data about physiotherapy and transport were missing. Drug costs were determined by 
using the price list in the drug compendium “Felleskatalogen 2007” or the 
pharmacists’ price quotes. We included the costs for four outpatient clinic 
consultations (baseline, four weeks after the start of PD-drugs, after six months, and 
after one year), as this would correspond to normal clinical practice in the catchment 
area of the Norwegian ParkWest study. The costs were calculated according to the 
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refunding rates to the clinics by the Norwegian Labour and Welfare Administration. 
The ICER was calculated by the ratio of these costs and the gain in QALY during the 
observation period. 
 
3.6 Statistical analysis 
Student’s t test was used to compare means for continuous variables and Chi-square 
test for testing differences in proportions for categorical variables. Two-sided p- 
values less that 0.05 were considered statistically significant.  
In paper 2 the observed curves for survival and nursing home admission were 
calculated by the Kaplan-Meier method. In the cross-sectional study the relative risk 
(RR) for living in a nursing home was obtained by dividing the share of patients 
living in nursing homes at baseline by the corresponding share of control individuals. 
In the longitudinal study the RR for being admitted to a nursing home was obtained 
by dividing the share of patients admitted to nursing homes during follow-up by the 
corresponding share of control individuals. The RR for living in a nursing home was 
obtained by dividing the share of time alive that was spent in nursing homes for 
patients with PD by the corresponding share for control individuals. 
In paper 3, the RR for in-hospital stay was calculated by dividing the mean number of 
in-hospital days per year of survival for patients with PD through the corresponding 
number of days for controls. 
In paper 4 the Mann-Whitney-U test was used to test for differences between 
independent and the Wilcoxon signed rank test for paired non-parametric variables. 
The confidence interval (CI) for the mean of the PD-drug costs was calculated by 
bootstrap analysis. 
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In paper 1, the software programs SPSS 11.0 (SPSS inc., Chicago, IL, USA) and 
STATA (StataCorp LP, College Station, TX, USA) were used for statistical analyses. 
In paper 2 and 3, the software program SPSS 14.0 and in paper 4 SPSS 15.0 was 
used. 
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4. Results 
4.1.1 Paper 1 
We found that drug expenses rose with disease duration and disease severity in both 
countries, but that expenses were markedly higher in the German cohort as compared 
to the Norwegian cohort with Euro 5.78 versus Euro 3.92 per patient and day. A 
higher proportion of the German patients were treated with two or more drugs, and 
the switch from mono- to multi-drug therapy was done earlier in the course of the 
disease. 
4.1.2 Paper 2 
Patients with PD had a 5-fold higher risk for living in a nursing home as compared to 
controls, both in the cross-sectional study at baseline and during the 12-year follow 
up. Based on 2007 prices, the incremental costs for institutional care were Euro 
14 897 per person year of survival. With a prevalence of 1.5 per 1000 population, 
costs for institutional care of patients with PD in Norway would come to Euro 132 
million per year. 
4.1.3 Paper 3 
Over the 12-year observation period there was no significant difference between 
patients with PD and controls regarding the number of individuals being admitted to 
hospital, numbers of admission, or length of stay. Incremental costs for the use of in-
hospital services were Euro 822 per year of survival for patients with PD, but the 
difference in costs between the two cohorts was statistically not significant. However, 
we found that patients with PD were more often admitted for trauma, while cardio-
vascular diseases and cancer were markedly more common in control individuals. 
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4.1.4 Paper 4 
Patients with PD had significantly lower health state values as compared to controls. 
Patients starting on antiparkinsonian drugs had an improvement in utility scores of 
0.039 from 0.667 to 0.706 during the one year follow-up. The  ICER was Euro 45 
259 per QALY for patients with incident PD during their first year of treatment, of 
which two thirds were caused by drugs and one third by costs for clinical 
consultations.  
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5. Discussion 
To evaluate the economic burden of a disease can be a problematic task, as the costs 
are compounded by many different factors. Some may be easy to assess, but in many 
cases accuracy is limited by either the selection of patients available for examination, 
or the lack of information about costs, or both. In an ideal world, a population-based 
patient cohort would have a confirmed diagnosis, would suffer only of the disease in 
question, would be treated according to standardized procedures, and all direct and 
indirect costs ever emerged to the individual would have been recorded in a stable 
health and social care system. Further, there would be a completely healthy control 
cohort where – of course – as well all costs have been recorded.  
The range of studies presented in chapter 1.3 illustrates some of the problems of 
economic evaluations: Health care systems and their refunding policies vary widely 
from country to country. Economic evaluations may therefore be difficult to transfer 
to other health care systems. Patient samples that are not population-based will be 
biased for disease severity, management, long-term complications, and need for care. 
Insurance claims as data source may give an incomplete picture of the real costs as 
they only reflect costs refunded by the health care system or private insurances. 
Formal care may be refunded by the health care system, private insurers or social 
care system, and refunding may cover all expenses or only parts of them. Availability 
and refunding will thus have an impact on the demand for formal care, both 
institutional and home care. Information about informal care relies on the correct 
report of the patients and their care givers. The refunding of informal care is debated 
in health economics and can range from prizing informal care the same as formal care 
to not prizing it at all but just indicating the hours spent. Indirect costs depend not 
only on the age composition of the patient sample but as well on a country’s sick 
leave regulations and pension system.  
The findings of our studies illustrate that the use of control cohorts adds valuable 
information to the evaluation of the burden of disease. In the developed countries, up 
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to 15% of the GNP is spent for health care services72. Thus, health is expensive and 
the findings that diseases cost a lot of money are not necessarily news. First when the 
consequences of a disease are seen in comparison to other patient groups or to the 
general population, a statement about the relative impact can be made. We could 
show that prescription habits may act as a cost driving factor when comparing two 
different countries to each other. We could further show that institutional care causes 
high incremental costs, but that in-hospital care by contrast did not cause incremental 
costs. Finally, we found that the treatment of incident PD has an ICER that is high 
but still within cost-effectiveness limits in Norway. 
 
5.1 Methodology 
Norway provides some conditions that are beneficial in performing health care 
research. First, there are only few private actors on the health care market. The use of 
health care services is therefore nearly completely registered by the state-run or 
municipality-run providers. Second, population density is low, and hospitals are often 
the sole health care institution within a radius of several hours’ driving and with large 
catchment areas. The Stavanger University Hospital serves as an exclusive provider 
for emergency care, in-hospital care, and specialized outpatient care for about 
320 000 people. Hospital files are thus reliable sources of information on a patient’s 
medical history. In addition, the department of Neurology at the Stavanger University 
Hospital is the initiator for a population-based longitudinal prevalence study about 
patients with PD that have been followed since 1993. Further, in 2004, a multi centre 
population-based longitudinal study on incident PD has been started in Western 
Norway. 
 
Patients and controls 
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A frequent problem in health economic evaluations is that information is drawn from 
selected patient populations as for example patients visiting specialized outpatient 
clinics, or patients participating in medical trials. Patients may thus have more 
advanced disease severity or at the contrary be rather healthy individuals with no co-
morbidity. To get a representative profile of patients we drew patients from 
population based studies or, in paper 1, from unselected patient groups. The control 
cohorts are drawn from the same catchment areas, thus ensuring that the availability 
and costs of nursing home placement, medical care and other socio-demographic 
factors were comparable. However, the control cohort in paper 4 was recruited 
among the patients’ relatives and friends, and these individuals volunteering to 
participate in a longitudinal study may constitute a control cohort that is healthier and 
in less need for care than the general population. At the same time it is known that 
primary caregivers of patients with PD experience a reduced quality of life100. In 
paper 2 and 3 we had to delay the observation period for the control cohort with one 
year for practical reasons. This may have caused bias between the patient and control 
cohort due to changes within the local health care services. Still, we considered the 
time lag of one year as compared to a 12-year observation period of minor impact. 
 
The assessment of costs 
In paper 2 we projected the total costs emerging from nursing home placement of 
patients with PD in Norway to society. Unfortunately, we were not able to assess the 
opportunity costs. Opportunity costs describe the costs occurring as compared to the 
second best alternative. In the case of institutional care, this would be a maximum of 
formal home care with four to six visits a day in addition to a certain amount of 
informal care.  
In paper 3 we presented costs as “Costs per patient and year” and “Costs per patient 
year of survival”. We chose both ways of presenting costs as they describe different 
aspects. i) “Costs per patients and year” describes the actual costs within a certain 
observation period. Individuals dying early may cause considerable costs while being 
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alive, but after death they do cause no additional costs. This method thus describes 
the costs emerging per incident individual. ii) “Costs per person year of survival” is a 
way of incorporating mortality into the calculation of costs. It thus describes the costs 
of a population with a certain disease and known prevalence. 
Both in paper 1 and in paper 4 we evaluate drug costs caused by the treatment of 
motor symptoms in PD. When assessing the incremental costs, these are the drugs 
most unequivocally related to the treatment of PD, while drugs used for non-motor 
symptoms like depression or cognitive impairment may as well be used for symptoms 
not related to PD. Thus, we did not assess all incremental costs caused by drug use in 
PD. As we compared two cohorts of patients with PD in paper 1, this issue is of 
minor importance. In paper 4 it might lead to an underestimation of the ICER. 
 
5.2 The evaluation of direct and indirect costs in PD 
We evaluated several aspects of direct costs in PD as drug costs, costs for 
neurological follow-up, costs caused by in-hospital care and costs caused by 
institutional care. We did not evaluate costs caused by transportation, costs for 
physiotherapy, therapeutic appliances, or adjustments at home. More importantly, we 
did not assess costs for formal home care or the amount of informal care; neither did 
we assess indirect costs due to loss of productivity. 
In regard to the total costs, our findings are in general agreement with previous 
observations. We found drug costs of Euro 5.78 per day for German patients and 
Euro 3.92 for Norwegian patients, while previous studies found daily drug costs 
between Euro 2.83 and Euro 5.5084-87.  The risk of living in a nursing home for 
patients with PD has been reported to be 4.6 and 6.7101, 102. In one study in the US 
incremental costs for institutional care were Euro 674793, while we found incremental 
costs of Euro 14 897. This difference may be partly due to different prices for nursing 
home placement. Unfortunately, annual prices for institutional care in the US are not 
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given in the paper cited. But as an example, prices for nursing home placement are 
twice as high in Norway as in the UK (personal communication). Costs for 
hospitalization have previously been found to be between Euro 1100 and 7400 per 
year (transferred to 2005 prices in EUR)83, 85, 86, 88, 90. With Euro 3300 our findings are 
in the middle range. Our findings do as well confirm  the findings of Parashos et al102, 
who found no increased risk for hospital admissions between patients with PD and 
controls during a 7.5-year follow-up, though other studies with shorter observation 
periods report increased risks of 1.44-fold and 3-fold, respectively92, 93. 
However, when looking at the incremental costs, our results cannot confirm the 
findings of previous studies. Several studies mention hospitalization as an important 
cost factor 85, 88, while we found no statistically significant incremental costs. Further, 
only few studies report the need for care as an important cost driving factor87, 94, 
while most of the presented studies either do not include direct non-medical costs or 
only have few patients in need for institutional care. We found that 14% of the 
patients with PD were living at a nursing home in a cross-sectional study and about 
half of the patients were admitted during a 12-year observation period. The need for 
care is thus a considerable cost driving factor, with incremental costs of Euro 14 897 
for nursing home placement, while incremental drug costs amounted to Euro 1430 
and incremental costs for hospitalization were Euro 822 and not statistical significant. 
 
5.3 Cost-effectiveness in the treatment of PD 
Cost-effectiveness can be evaluated in monetary terms, with one treatment option 
being cheaper than the alternative while not being less effective. However, a 
treatment option can as well be regarded as cost-effective when the results obtained 
seem to be worth the expenses. In cost-utility analysis, results are expressed in 
QALYs as a measurement for gains or losses in health states. The incremental cost-
effectiveness ratio (ICER) evaluates the costs per QALY gained. It is then up to the 
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decision maker to decide whether these costs can be considered cost-effective. 
Different countries may have differing cut offs for what is being considered cost-
effective. An acceptable price per QALY lies around Euro 30 000 in the UK, Euro 
50 000 in the US and Euro 60 000 in Norway. 
The evaluation of the impact of 29 chronic conditions on the health states in a Finnish 
population using the EQ-5D showed that PD had the largest negative effect on the 
health state at the individual level, while due to prevalence, musculoskeletal disorders 
have the greatest impact on a population level103 A review from 2006 on HR-QoL 
and the economic impact of PD showed that there are few studies evaluating cost-
effectiveness by using QALYs as an outcome measurement104. Only one study 
evaluating the cost-effectiveness of surgery in PD was conducted as a cost-utility 
study finding that surgery was cost-effective if the improvement in the quality of life 
was more than 18%105. A later study on the same subject found as well that surgery 
was cost-effective as compared to best medical treatment with an ICER of Euro 
34 389 per QALY106. Of the studies evaluating cost-effectiveness in drug treatment 
of PD, seven of ten used a Markov model. In three studies patient cohorts were 
examined, evaluating the cost effectiveness of pramipexole, ropinirole and sustained-
release carbidopa-levodopa, respectively, as compared to levodopa107-109, but only 
one study was conducted as a cost-utility study using the EQ-5D as measurement of 
health states107. To our knowledge, no study evaluating the ICER of PD treatment in 
an unselected patient population has been conducted until now. Schrag et al. 
evaluated the health state values of 93 patients drawn from a population-based cross-
sectional study finding a median EQ-5D score of 0.62110. We found an improvement 
of the SF-6D score of 0.039 from 0.667 to 0.706 during the first year of drug 
treatment in newly diagnosed PD and an ICER of Euro 45 259 per QALY. 
5.4 Future research 
In this thesis we put emphasis on the use of control cohorts. The comparison between 
diseased and healthy individuals, hence the incremental costs, are a more valid 
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measurement of the economic burden of a disease than the statement of the absolute 
costs, as the costs caused by age-related morbidity are subtracted. According to our 
numbers, care is by far the largest factor of the direct costs in PD. Costs for 
institutional care are 10-fold higher than the costs for drug treatment. Formal care is 
not only costly but requires as well trained staff that needs to be recruited and 
educated and that in consequence will lead to a lack of work force in other sectors. 
Our findings implicate that interventions that enhance independency in ADL and 
prevent nursing home admissions probably will be cost-effective. They suggest as 
well that informal caregivers should receive optimal support to avoid 
institutionalization. Caregivers often experience a reduced quality of life100, 104, 111 and 
caregivers’ stress increases the risk for nursing home admission112. Measures like 
specialized PD nurses, information seminars, patient and caregiver networks, and 
thorough medical follow-up may contribute to provide optimal treatment conditions 
and to increase the quality of life of both patients and their caregivers. 
Future research should evaluate the amount of formal and informal home care 
patients with PD receive as compared to the general population. Further, intervention 
studies should examine the potential for preventing nursing home admissions and 
decreasing the amount of home care. At the same time, the quality of life of 
caregivers is an important issue, and a reduction in formal care must not transfer the 
burden to the informal caregivers. Possible interventions may include the decrease of 
disease progression, improved drug management in late-stage PD, support of 
informal caregivers by enhanced networks, home visits of PD nurses and the relief of 
strain on the caregivers by day care centers.  
Furthermore, we could show that the ICER of drug treatment in incident PD is high. 
However, the full evaluation of the effectiveness of drug treatment should include the 
long-term effects on disease progression and thus the need for care. Longitudinal 
studies following patients during the whole course of the disease will be necessary to 
provide conclusive data.  
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6. Conclusion 
The aim of this thesis was to obtain more knowledge about the direct costs causes by 
PD. For this purpose we examined various populations of patients with PD and 
controls in both cross-sectional and longitudinal study designs. 
In the first study we compared a German and a Norwegian cohort of patients with PD 
with regard to drug use, drug costs and prescription habits. We found that drug 
expenses rose with disease duration and disease severity in both groups, but that 
expenses were markedly higher in the German group and the switch from mono- to 
multi-drug therapy was done earlier in the course of the disease.  
In the second study we followed a population-based cohort of patients with PD and a 
control cohort over a period of 12 years finding that the risk for living in a nursing 
home was 5-fold increased for patients with PD as compared to controls, both in a 
cross-sectional study at baseline and during follow-up. The incremental costs for 
institutional care were Euro 14 897 per patient year of survival for patients with PD. 
In the third study we followed the same patients and controls as in study 2 finding 
that there was no significantly increased risk for hospitalization for patients with PD 
as compared to controls and thus no incremental costs related to in-hospital care. 
However, we found that patients with PD were more often admitted for trauma, while 
cardiovascular disease and cancer were more common in control individuals. 
In the fourth study we examined the health state values and treatment costs in a 
population-based cohort of patients with incident PD during the first year of drug 
management. We showed that the patients with PD had lower health state values than 
the age- and sex-matched control cohort, but that health state values were improved 
by medical treatment. The ICER was Euro 45 259 per QALY, of which two thirds 
were caused by drug costs and one third by costs for clinical consultations. 
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In conclusion, we could show that disease management requires constant evaluation, 
in regard of the quality of treatment as well as of cost-effectiveness. We could further 
show that the use of control cohorts adds valuable information to the evaluation of 
the burden of disease and helps to discern costs related to a certain disease from costs 
caused by general age-related morbidity. Our findings confirm that the need for 
formal and informal care of patients suffering from chronic progressive diseases will 
be a major challenge for health and social care systems in the years to come. 
However, more research is necessary to evaluate the full burden of PD and to explore 
efficacy and effectiveness of the disease management. 
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